Copyright © 2014 FDC.
All Rights Reserved
August 22, 2008
The Board of Directors of the Company at its meeting held on August 12, 2008, have approved the B uyback of its fully paid equity shares, from the open market, through the stock exchanges, at a price not exceeding Rs.40/- per share, up to an amount of Rs.3,585.96 lakhs being 10% of the total paid up capital and free reserves as per audited balance sheet for the year ended March 31, 2008.
The Buyback would be subject to, inter-alia, the promoter and promoter group being granted exemption under SEBI (Substantial Acquisition of Shares and Takeover) Regulations, 1997.
August 04, 2008
"This is to inform you that a meeting of the Board of Directors of the Company is scheduled to be held on Tuesday, August 12, 2008 at the Corporate Office of the Company at Mumbai to consider the Buy back of equity shares of the Company."
July 17, 2008
FDC recently received the prestigious CE certification for yet another product:
SODIUM HYALURONATE Eye Drops (Hymoist Eye Drops).
FDC earlier obtained two CE markings in the regulated European market for:
HYPROMELLOSE Eye Drops & I-LUBE Eye Drops
FDC successfully received re-certification for
ISO 9001:2000 & ISO 13485:2003.
This re-certification is awarded for maintenance and implementation of Quality Management Systems relating to: Design, Development, Manufacturing and Sale of Pharmaceutical Products as well as Medical Devices.
July 02, 2008
FDC Limited, leaders in the field of ophthalmology, achieves another milestone!!!
FDC Limited has now received an approval from the U.S. FDA for its Abbreviated New Drug Application (ANDA), Ciprofloxacin Ophthalmic Solution. Ciprofloxacin Ophthalmic Solution is a broad spectrum antibiotic used for occular surface infections.
As announced earlier the Company had recently received approval for Timolol Maleate Ophthalmic Solution. Another ANDA Ofloxacin Ophthalmic Solution is in the final stages of approval.
May 09, 2008
FDC Limited, leaders in the field of ophthalmology, soars high with the nod it received from the U.S. FDA for its Abbreviated New Drug Application (ANDA), Timolol Maleate Ophthalmic Solution. Timolol Maleate is a nonselective beta-blocking drug, used as a primary line of treatment for glaucoma.
The Company's other two ANDAs Ciprofloxacin Ophthalmic Solution and Ofloxacin Ophthalmic Solution are in the pipeline, in the final stages of approval. Besides these three ANDAs, FDC also has on its anvil around five more products at an advanced stage of filing.
FDC has also to its credit twelve DMF's (Drug Master Files) and ten Marketing Authorizations in UK .